We welcome talented individuals who embrace our commitment to patients in need and share our values. Our success is determined by collective diversity of thoughts, skills and experiences.
As a team, we foster innovation in all forms as we collectively strive to discover and develop new approaches to treating severe rare diseases.
At our core, we dive deep into the science of severe rare diseases, holding ourselves to the highest scientific standards and best practices to bring those discoveries through approval and to patients in need.
The patients we serve are very ill. We will not waver in our commitment to them, their families and their healthcare providers.
Drug development takes a village, and we know we cannot succeed unless our entire team and partners join together to bring therapies from discovery into patients’ hands.
We value diversity of professions, backgrounds and cultures, understanding that each of us has a respected insight and perspective on our work and our vision.
Our team is built on agility and flexibility, adjusting to opportunities and needs of the business quickly and comfortably.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a publicly traded, clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. Our pipeline includes two clinical-stage compounds: SCY-770, a novel, highly selective direct AMPK activator in development for autosomal dominant polycystic kidney disease (ADPKD), and SCY-247, a second-generation triterpenoid antifungal candidate currently in Phase 1 development for the treatment and prevention of invasive fungal infections.
We are seeking an experienced Director, Drug Product Development, to be based in our Jersey City, NJ office. This role will lead drug product strategy and execution across our clinical-stage portfolio, supporting the advancement of innovative therapies for patients with serious rare diseases.
The Director, Drug Product Development will lead formulation, manufacturing, and lifecycle activities for drug product candidates from development through clinical-stage execution. This role partners across CMC, Quality, Regulatory, Supply Chain, and external manufacturers to ensure drug products are robust, scalable, and aligned with program timelines and regulatory requirements.
SCYNEXIS is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, age, religion, sex, sexual orientation, gender identity, national origin, disability, veteran status or other characteristics protected by law.
The starting pay for this role is between $200,000.00 and $235,000.00. The estimated salary range represents an anticipated range for this position. The actual base salary offered may vary based on a variety of factors.
We offer a competitive total rewards package that includes short-term and long-term incentive programs and a comprehensive benefits package, including medical, dental, and vision coverage, a 401(k) with company match, paid time off, and additional benefits.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a publicly traded, clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. Our pipeline includes two clinical-stage compounds: SCY-770, a novel highly selective direct AMPK activator in development for autosomal dominant polycystic kidney disease (ADPKD), and SCY-247, a second-generation triterpenoid antifungal candidate currently in Phase 1 development for the treatment and prevention of invasive fungal infections.
We are seeking an experienced Manager, Preclinical Operations to be based in our Jersey City, NJ office. Reporting to the Director, Program Management, this role will oversee the operational execution of outsourced preclinical development activities, ensuring studies are delivered efficiently, compliantly, and in alignment with program and regulatory objectives defined by cross-functional leaders.
The Manager, Preclinical Operations is responsible for the planning, coordination, execution, and oversight of outsourced preclinical studies that support SCYNEXIS’ development programs. This role manages the operational aspects of study delivery across pharmacology, toxicology, DMPK/ADME, and bioanalysis activities, ensuring studies are appropriately scoped, contracted, scheduled, tracked, and completed on time, within budget, and in accordance with quality, regulatory, and compliance requirements. The position serves as the primary operational interface between internal functional teams and external CROs, laboratories, consultants, and service providers, driving day-to-day execution, issue resolution, and study progress across multiple concurrent development activities.
This is an operations-focused role rather than a scientific research position and requires strong project management, vendor oversight, cross-functional coordination, budget management, and organizational skills.
SCYNEXIS is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, age, religion, sex, sexual orientation, gender identity, national origin, disability, veteran status, or other characteristics protected by law.
The starting pay for this role is between $125,000.00 and $150,000.00. The estimated salary range represents an anticipated range for this position. The actual base salary offered may vary based on a variety of factors.
We offer a competitive total rewards package that includes short-term and long-term incentive programs and a comprehensive benefits package, including medical, dental, and vision coverage, a 401(k) with company match, paid time off, and additional benefits.